Kodiak Sciences股价大涨145%,因Zenkuda和KSI-501在湿性AMD3期试验中达成目标。这一后期试验成功是Kodiak Sciences在湿性AMD领域的临床里程碑。引述“Kodiak Sciences股价暴涨145%,因Zenkuda和KSI-501达成湿性AMD3期目标。”— Seekingalpha来源Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trialSeekingalpha